Cited by 670Adenosine and Purinergic SignalingBiochemical and Molecular Researchbioluminescence and chemiluminescence research

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase

Open access

Abstract

BACKGROUND: There is growing awareness that tumour cells build up a "self-advantageous" microenvironment that reduces effectiveness of anti-tumour immune response. While many different immunosuppressive mechanisms are likely to come into play, recent evidence suggests that extracellular adenosine acting at A2A receptors may have a major role in down-modulating the immune response as cancerous tissues contain elevated levels of adenosine and adenosine break-down products. While there is no doubt that all cells possess plasma membrane adenosine transporters that mediate adenosine uptake and may also allow its release, it is now clear that most of extracellularly-generated adenosine originates from the catabolism of extracellular ATP. METHODOLOGY/PRINCIPAL FINDINGS: Measurement of extracellular ATP is generally performed in cell supernatants by HPLC or soluble luciferin-luciferase assay, thus it generally turns out to be laborious and inaccurate. We have engineered a chimeric plasma membrane-targeted luciferase that allows in vivo real-time imaging of extracellular ATP. With this novel probe we have measured the ATP concentration within the tumour microenvironment of several experimentally-induced tumours. CONCLUSIONS/SIGNIFICANCE: Our results show that ATP in the tumour interstitium is in the hundreds micromolar range, while it is basically undetectable in healthy tissues. Here we show that a chimeric plasma membrane-targeted luciferase allows in vivo detection of high extracellular ATP concentration at tumour sites. On the contrary, tumour-free tissues show undetectable extracellular ATP levels. Extracellular ATP may be crucial for the tumour not only as a stimulus for growth but also as a source of an immunosuppressive agent such as adenosine. Our approach offers a new tool for the investigation of the biochemical composition of tumour milieu and for development of novel therapies based on the modulation of extracellular purine-based signalling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0002599

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Imaging of healthy nude mice i.v. injected with HEK293-pmeLUC cells. Mice were injected i.v. with 2×106 HEK293-pmeLUC cells. D-luciferin was administred intraperitoneally. Images were captured 15 minutes after D-luciferin administration. Acquisition time was 3 min, and images were acquired over 2 months every 2 days both from the dorsal (A) and the ventral (B) view. The earliest time point was at 15 min after D-luciferin injection. Only images taken after 1, 3, 15 and 42 days are shown.
Figure 1 Imaging of healthy nude mice i.v. injected with HEK293-pmeLUC cells. Mice were injected i.v. with 2×106 HEK293-pmeLUC cells. D-luciferin was administred intraperitoneally. Images were captured 15 minutes after D-luciferin administration. Acquisition time was 3 min, and images were acquired over 2 months every 2 days both from the dorsal (A) and the ventral (B) view. The earliest time point was at 15 min after D-luciferin injection. Only images taken after 1, 3, 15 and 42 days are shown.CC BY · PubMed Central
Figure 2 Imaging of tumour-bearing nude mice injected with HEK293-pmeLUC cells. (A) Healthy nude mice were injected i.p. with 2×106 HEK293-pmeLUC cells and monitored for 3 months (only 4 time points are shown). (B) Nude mice were injected i.p. with the human ovarian carcinoma cell line OVCAR-3 (1.5×106). Twenty days post-implantation, HEK293-pmeLUC cells (2×106) were i.p. injected, followed by D-luciferin. OVCAR-3-bearing mice were monitored over 16 days, and were then euthanized according to bioethical regulations.
Figure 2 Imaging of tumour-bearing nude mice injected with HEK293-pmeLUC cells. (A) Healthy nude mice were injected i.p. with 2×106 HEK293-pmeLUC cells and monitored for 3 months (only 4 time points are shown). (B) Nude mice were injected i.p. with the human ovarian carcinoma cell line OVCAR-3 (1.5×106). Twenty days post-implantation, HEK293-pmeLUC cells (2×106) were i.p. injected, followed by D-luciferin. OVCAR-3-bearing mice were monitored over 16 days, and were then euthanized according to bioethical regulations.CC BY · PubMed Central
Figure 3 HEK293-pmeLUC cells localize to tumour foci. (A) Mice were euthanized, the peritoneal cavity was opened and imaged. (B) Single tumour foci were excised and luminescence recorded. (C) Tissue section from one of the tumour foci stained with haematoxylin/eosin. (D) Cytofluorimetric analysis of cells isolated from tumour foci. Staining was performed with monoclonal FITC-labeled rabbit anti-luciferase (red trace on the left panel) or anti-CD51 (red trace on the right panel) Abs. Irrelevant IgG1 Ab (grey trace on both the right and left panel) was used as control. (E) Expression of pmeLUC mRNA in tumour foci excised from mice injected with OVCAR-3 and HEK293-pmeLUC cells. OVCAR-3 and HEK293-pmeLUC cells grown in culture are shown as controls. RT-PCR was performed as described in Materials and Methods.
Figure 3 HEK293-pmeLUC cells localize to tumour foci. (A) Mice were euthanized, the peritoneal cavity was opened and imaged. (B) Single tumour foci were excised and luminescence recorded. (C) Tissue section from one of the tumour foci stained with haematoxylin/eosin. (D) Cytofluorimetric analysis of cells isolated from tumour foci. Staining was performed with monoclonal FITC-labeled rabbit anti-luciferase (red trace on the left panel) or anti-CD51 (red trace on the right panel) Abs. Irrelevant IgG1 Ab (grey trace on both the right and left panel) was used as control. (E) Expression of pmeLUC mRNA in tumour foci excised from mice injected with OVCAR-3 and HEK293-pmeLUC cells. OVCAR-3 and HEK293-pmeLUC cells grown in culture are shown as controls. RT-PCR was performed as described in Materials and Methods.CC BY · PubMed Central
Figure 4 Comparison of luminescence emission from HEK293-pmeLUC and HEK293-cytLUC cells injected into MZ2-MEL melanoma and healthy tissue. Nude mice were inoculated with MZ2-MEL cells in the right dorsal hip. After about 20 days, when the tumour was about 1–1.5×1–1.5 cm size, HEK293-pmeLUC (A) or HEK293-cytLUC (B) cells were injected s.c. into the tumour bearing (right) or healthy (left) site.
Figure 4 Comparison of luminescence emission from HEK293-pmeLUC and HEK293-cytLUC cells injected into MZ2-MEL melanoma and healthy tissue. Nude mice were inoculated with MZ2-MEL cells in the right dorsal hip. After about 20 days, when the tumour was about 1–1.5×1–1.5 cm size, HEK293-pmeLUC (A) or HEK293-cytLUC (B) cells were injected s.c. into the tumour bearing (right) or healthy (left) site.CC BY · PubMed Central
Figure 5 Luciferase expression by HEK293-pmeLUC and HEK293-cytLUC. Plasma membrane (A) or cytosolic (B) luciferase expression was analyzed with a specific anti-luciferase Ab (see Figure 3). An isotype-matched control mAb was used as control. Luciferase expression is reported as percentage of positive cells.
Figure 5 Luciferase expression by HEK293-pmeLUC and HEK293-cytLUC. Plasma membrane (A) or cytosolic (B) luciferase expression was analyzed with a specific anti-luciferase Ab (see Figure 3). An isotype-matched control mAb was used as control. Luciferase expression is reported as percentage of positive cells.CC BY · PubMed Central
Figure 6 Sensitivity of HEK293-pmeLUC cells to apyrase. A melanoma was induced as described in Figure 4, and inoculated with HEK293-pmeLUC cells 20 days after implant. Apyrase (20 U in 40 µl of serum free DMEM ) or vehicle (serum free DMEM) was injected into the tumour four days later. Bioluminescence was recorded as indicated. (A) Apyrase-injected, or (B) vehicle-injected mice. (C) Quantitative analysis of light emission from region-of-interest. Data are averages of measurements from 4 mice (n = 4). * p<0.05 (paired t-test).
Figure 6 Sensitivity of HEK293-pmeLUC cells to apyrase. A melanoma was induced as described in Figure 4, and inoculated with HEK293-pmeLUC cells 20 days after implant. Apyrase (20 U in 40 µl of serum free DMEM ) or vehicle (serum free DMEM) was injected into the tumour four days later. Bioluminescence was recorded as indicated. (A) Apyrase-injected, or (B) vehicle-injected mice. (C) Quantitative analysis of light emission from region-of-interest. Data are averages of measurements from 4 mice (n = 4). * p<0.05 (paired t-test).CC BY · PubMed Central
Figure 7 In vitro calibration of HEK293-pmeLUC bioluminescence. (A) HEK293-pmeLUC cells, 7×104 per well, were incubated in DMEM medium and challenged with increasing concentrations of extracellular ATP and luminescence acquired with the IVIS luminometer for 1 min. In (B) luminescence (total flux expressed as photon per sec) was expressed as a function of the ATP concentration. Control well contained only DMEM medium. D-luciferin was added to all wells at a concentration of 60 µg/ml.
Figure 7 In vitro calibration of HEK293-pmeLUC bioluminescence. (A) HEK293-pmeLUC cells, 7×104 per well, were incubated in DMEM medium and challenged with increasing concentrations of extracellular ATP and luminescence acquired with the IVIS luminometer for 1 min. In (B) luminescence (total flux expressed as photon per sec) was expressed as a function of the ATP concentration. Control well contained only DMEM medium. D-luciferin was added to all wells at a concentration of 60 µg/ml.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

Sorted by citations

Items 501–600 of 670

Metadata

Authors
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F.
Affiliations
  • University of Ferrara (IT)
  • Istituto Giannina Gaslini (IT)
Venue
PLoS ONE
Published
2008-07-09
Volume
3
Issue
7
Pages
e2599
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2070663123
Cited by
668
References
28
Citations by year
2026: 31 · 2025: 40 · 2024: 29 · 2023: 62 · 2022: 51 · 2021: 58 · 2020: 66 · 2019: 42 · 2018: 37 · 2017: 34 · 2016: 33 · 2015: 25 · 2014: 36 · 2013: 28 · 2012: 40
FWCI
11.40
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
Funders
  • Fondazione Italiana per la Lotta al Neuroblastoma
  • Associazione Italiana per la Ricerca sul Cancro (GGP06070)
  • Università degli Studi di Ferrara
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › bioluminescence and chemiluminescence research
Keywords
extracellular ATP, tumor microenvironment, in vivo imaging, adenosine, adenosine A2A receptor, immunosuppression, ATP catabolism, adenosine transporter
MeSH terms
Adenosine Triphosphate, Animals, Cell Membrane, Extracellular Space, Humans, Luciferases, Luminescent Measurements, Mice, Nude, Neoplasms, Cell Line, Tumor, Luminescent Agents, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review